RASSF1A and SIRT6 in non-small cell lung cancer: Relationship with clinical outcome

Chen,Tao; Sun,Zhaojun; Liu,Fengling; Wang,Qiang

doi:10.3892/ol.2017.6172

RASSF1A and SIRT6 in non-small cell lung cancer: Relationship with clinical outcome

Authors:
- Tao Chen
- Zhaojun Sun
- Fengling Liu
- Qiang Wang
View Affiliations

Affiliations: The Second Department of Surgery, Chinese Medicine Hospital in Linyi City, Linyi, Shandong 276002, P.R. China
Published online on: May 15, 2017 https://doi.org/10.3892/ol.2017.6172
Pages: 5759-5764
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study investigated the expression of RASSF1A and SIRT6 in non-small cell lung cancer (NSCLC) and its relationship with clinical prognosis. The expression in 122 cases of NSCLC tissues (NSCLC group) and 122 cases of normal lung tissues (NOR group) during the same period were detected by immunohistochemical Super Pic TureTM Polymer two-step method, and the relationship between its expression and the clinicopathological features and prognosis of patients was analyzed. The positive expression rates of RASSF1A and SIRT6 in NSCLC group were lower than those in the normal group (55.74 vs. 84.43% and 52.46 vs. 82.49%, P<0.01). The differences in expression intensity of RASSF1A in NSCLC tissues between different tumor pathological types, tumor differentiation degrees and lymph node metastases were statistically significant, and the differences in expression intensity of SIRT6 between different TNM stages, tumor differentiation degrees and lymph node metastases were statistically significant. There was a positive correlation between the expression of RASSF1A and SIRT6 in NSCLC group (r=0.532, P<0.01). The 3-year survival rate of patients with high-expression of RASSF1A was higher than in those with low-expression of RASSF1A (81.33 vs. 39.45%, log-rank χ2=19,102, P<0.01); the 3-year survival rate of patients with high-expression of SIRT6 was higher than in those with low-expression of SIRT6 (83.51 vs. 42.43%, log‑rank χ2=17,180, P<0.01). The low expression of RASSF1A and SIRT6 and lymph node metastasis were the risk factors affecting the prognosis of NSCLC patients. There is a better correlation between the expression of RASSF1A and SIRT6 in NSCLC tissues, and the detection of their expression is of great significance in the judgement of clinicopathological features and prognosis of NSCLC patients.

View Figures

View References

1	Leong D, Rai R, Nguyen B, Lee A and Yip D: Advances in adjuvant systemic therapy for non-small-cell lung cancer. World J Clin Oncol. 5:633–645. 2014. View Article : Google Scholar : PubMed/NCBI
2	Jing W, Li N, Wang Y, Liu X, Liao S, Chai H and Tu J: The prognostic significance of long noncoding RNAs in non-small cell lung cancer: A meta-analysis. Oncotarget. 8:3957–3968. 2016.
3	Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Dilling TJ, et al: NCCN guidelines insights: Non-small cell lung cancer, version 4.2016. J Natl Compr Canc Netw. 14:255–264. 2016. View Article : Google Scholar : PubMed/NCBI
4	Douillard JY, Lehur PA, Vignoud J, Blottière H, Maurel C, Thedrez P, Kremer M and Le Mevel B: Monoclonal antibodies specific immunotherapy of gastrointestinal tumors. Hybridoma. 5 Suppl 1:S139–S149. 1986.PubMed/NCBI
5	Dallol A, Agathanggelou A, Tommasi S, Pfeifer GP, Maher ER and Latif F: Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. Cancer Res. 65:7653–7659. 2005. View Article : Google Scholar : PubMed/NCBI
6	Deng ZH, Zhou JH, Cao HQ, Sheng M and Weng JF: Proliferation inhibition of human lung adenocarcinoma cell line A549 transfected by RASSF1A gene. J Cent South Univ (Med Sci). 30:193–196. 2005.
7	Han Z, Liu L, Liu Y and Li S: Sirtuin SIRT6 suppresses cell proliferation through inhibition of Twist1 expression in non-small cell lung cancer. Int J Clin Exp Pathol. 7:4774–4781. 2014.PubMed/NCBI
8	Fukatsu A, Ishiguro F, Tanaka I, Kudo T, Nakagawa K, Shinjo K, Kondo Y, Fujii M, Hasegawa Y, Tomizawa K, et al: RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer. Lung Cancer. 83:23–29. 2014. View Article : Google Scholar : PubMed/NCBI
9	Avruch J, Praskova M, Ortiz-Vega S, Liu M and Zhang XF: Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases. Methods Enzymol. 407:290–310. 2006. View Article : Google Scholar : PubMed/NCBI
10	Dubois F, Keller M, Calvayrac O, Soncin F, Hoa L, Hergovich A, Parrini MC, Mazières J, Vaisse-Lesteven M, Camonis J, et al: RASSF1A suppresses the invasion and metastatic potential of human non-small cell lung cancer cells by inhibiting YAP activation through the GEF-H1/RhoB pathway. Cancer Res. 76:1627–1640. 2016. View Article : Google Scholar : PubMed/NCBI
11	Whang YM, Park KH, Jung HY, Jo UH and Kim YH: Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines. Cancer. 115:1253–1266. 2009. View Article : Google Scholar : PubMed/NCBI
12	Chen K, Li BK, Xu K, Xu A, Liu C, Zheng S, Xu Y, Jia C, Liu Q, Li Η, et al: Effect of stable DNA methyltransferase 3b knockdown on proliferation and apoptosis in bladder cancer cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao. 35:1524–1529. 2015.(In Chinese). PubMed/NCBI
13	Huang YZ, Wu W, Wu K, Xu XN and Tang WR: Association of RASSF1A promoter methylation with lung cancer risk: A meta-analysis. Asian Pac J Cancer Prev. 15:10325–10328. 2014. View Article : Google Scholar : PubMed/NCBI
14	Fu L and Zhang S: RASSF1A promotes apoptosis and suppresses the proliferation of ovarian cancer cells. Int J Mol Med. 33:1153–1160. 2014. View Article : Google Scholar : PubMed/NCBI
15	Ko E, Lee BB, Kim Y, Lee EJ, Cho EY, Han J, Shim YM, Park J and Kim DH: Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I–II non-small cell lung cancer. Clin Cancer Res. 19:1204–1212. 2013. View Article : Google Scholar : PubMed/NCBI
16	Dittfeld C, Richter AM, Steinmann K, Klagge-Ulonska A and Dammann RH: The SARAH domain of RASSF1A and its tumor suppressor function. Mol Biol Int. 2012:1967152012. View Article : Google Scholar : PubMed/NCBI
17	Pastuszak-Lewandoska D, Kordiak J, Migdalska-Sęk M, Czarnecka KH, Antczak A, Górski P, Nawrot E, Kiszałkiewicz JM, Domańska D and Brzeziańska-Lasota E: Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients. Respir Res. 16:762015. View Article : Google Scholar : PubMed/NCBI
18	Bai L, Lin G, Sun L, Liu Y, Huang X, Cao C, Guo Y and Xie C: Upregulation of SIRT6 predicts poor prognosis and promotes metastasis of non-small cell lung cancer via the ERK1/2/MMP9 pathway. Oncotarget. 7:40377–40386. 2016. View Article : Google Scholar : PubMed/NCBI
19	Azuma Y, Yokobori T, Mogi A, Altan B, Yajima T, Kosaka T, Onozato R, Yamaki E, Asao T, Nishiyama M, et al: SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer. J Surg Oncol. 112:231–237. 2015. View Article : Google Scholar : PubMed/NCBI
20	Cai Y, Sheng ZY and Liang SX: Radiosensitization effect of overexpression of adenovirus-mediated SIRT6 on A549 non-small cell lung cancer cells. Asian Pac J Cancer Prev. 15:7297–7301. 2014. View Article : Google Scholar : PubMed/NCBI
21	Bae JS, Park SH, Jamiyandorj U, Kim KM, Noh SJ, Kim JR, Park HJ, Kwon KS, Jung SH, Park HS, et al: CK2α/CSNK2A1 phosphorylates SIRT6 and is involved in the progression of breast carcinoma and predicts shorter survival of diagnosed patients. Am J Pathol. 186:3297–3315. 2016. View Article : Google Scholar : PubMed/NCBI
22	Bhardwaj A and Das S: SIRT6 deacetylates PKM2 to suppress its nuclear localization and oncogenic functions. Proc Natl Acad Sci USA. 113:E538–E547. 2016. View Article : Google Scholar : PubMed/NCBI
23	Demir IE, Ceyhan GO and Friess H: Epigenomic therapies: The potential of targeting SIRT6 for the treatment of pancreatic cancer. Expert Opin Ther Targets. 21:1–3. 2017. View Article : Google Scholar : PubMed/NCBI
24	Lee N, Ryu HG, Kwon JH, Kim DK, Kim SR, Wang HJ, Kim KT and Choi KY: SIRT6 depletion suppresses tumor growth by promoting cellular senescence induced by DNA damage in HCC. PLoS One. 11:e01658352016. View Article : Google Scholar : PubMed/NCBI
25	Wolf K and Strand S: Assessing the histone deacetylase activity of SIRT6 in primary murine hepatocytes via proximity ligation assay. Methods Mol Biol. 1510:149–158. 2017. View Article : Google Scholar : PubMed/NCBI
26	Thaler S, Hähnel PS, Schad A, Dammann R and Schuler M: RASSF1A mediates p21^Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt. Cancer Res. 69:1748–1757. 2009. View Article : Google Scholar : PubMed/NCBI
27	Romano D, Matallanas D, Weitsman G, Preisinger C, Ng T and Kolch W: Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res. 70:1195–1203. 2010. View Article : Google Scholar : PubMed/NCBI
28	Sundaresan NR, Vasudevan P, Zhong L, Kim G, Samant S, Parekh V, Pillai VB, Ravindra PV, Gupta M, Jeevanandam V, et al: The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat Med. 18:1643–1650. 2012. View Article : Google Scholar : PubMed/NCBI